Safety and efficacy of mizoribine treatment in nephrotic syndrome complicated with hepatitis B virus infection: a clinical study

Figures & data

Table 1. Clinical remission rates in patients with different renal pathologies (n).

Remission	MCD	MsPGN	MN	FSGS	IgAN				Total
					Stage II	Stage III	Stage IV	Stage V
CR	2	5	3	1	2	4	0	0	17
PR	0	3	2	2	1	3	0	0	11
Failure	0	0	1	5	0	0	1	1	8
Total	2	8	6	8	3	7	1	1	36

Figure 1. Efficacies of MZR in treating nephrotic syndrome accompanied with HBV infection.

Figure 2. Mizoribine therapy: serum AlB levels in patients with HBV-positive nephrotic syndrome.

Figure 3. Mizoribine therapy: 24 h-U-TP levels in patients with HBV-positive nephrotic syndrome.

Figure 4. Mizoribine therapy: serum cholesterol levels in patients with HBV-positive nephrotic syndrome.

Figure 5. Mizoribine therapy: serum TG levels in patients with HBV-positive nephrotic syndrome.

Table 2. Efficacy of mizoribine in treating nephrotic syndrome plus HBV infection.

	AlB (g/L)	ALT (U/L)	CHOL (mmol/L)	TG (mmol/L)	BUN (mmol/L)	SCr (μmol/L)	24h-U-TP (g/L)
Before treatment	17 ± 4.23	36 ± 5.82	6.03 ± 0.56	3.83 ± 0.86	7.6 ± 3.6	85 ± 24.7	5.94 ± 0.63
2-week of treatment	24 ± 3.98*	32 ± 4.13	5.17 ± 0.38	2.84 ± 0.71	7.2 ± 2.4	79 ± 20.5	4.57 ± 0.54*
4-week of treatment	26 ± 4.18*	27 ± 6.18	4.08 ± 0.64	2.06 ± 0.65	6.6 ± 3.2	81 ± 28.6	4.35 ± 0.46*
8-week of treatment	30 ± 6.72^△	29 ± 5.11	3.89 ± 0.76	1.68 ± 0.38	6.4 ± 4.5	74 ± 23.8	2.48 ± 0.38^△
12-week of treatment	29 ± 5.44*	23 ± 4.96	3.76 ± 0.82	1.41 ± 0.66	5.8 ± 4.7	76 ± 19.3	2.25 ± 0.52^△
16-week of treatment	31 ± 7.65^△	25 ± 5.27	3.95 ± 0.67	1.37 ± 0.39	4.9 ± 4.2	72 ± 20.8	1.66 ± 0.67^△
20-week of treatment	35 ± 5.31^△	24 ± 3.96	3.42 ± 0.86*	1.29 ± 0.68	5.2 ± 3.7	69 ± 28.4	1.43 ± 0.71^△
24-week of treatment	34 ± 6.87^△	26 ± 4.21	3.23 ± 0.91*	1.13 ± 0.54*	6.1 ± 5.3	80 ± 22.9	1.09 ± 0.78^△

*p < 0.05,

△ p < 0.01, compared with pretreatment level.

Figure 6. Mizoribine therapy: altered HBV-DNA titer in patients with HBV-positive nephrotic syndrome.